An earlier report has demonstrated that when HER2, EGFR and HER4 were inhibited using tyrosine kinase (TK) inhibitors, HER3 was upregulated, and this appeared to facilitate cancer cell survival and proliferation [43]. This evidence concerns the gene ERBB2 and cancer.